Phase IV Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis

834149

This study will be an open label study of secukinumab for the treatment of nail psoriasis. Secukinumab is an FDA-approved treatment for psoriasis. We will examine time to response and different methods of defining nail disease response.

2022-02-07

2025-12-01

2025-12-01

Recruiting

Early phase I

40

Inclusion Criteria: * Active psoriatic nail disease defined as a Minimum 4 or more fingernails OR NAPSI\>20 * Active skin psoriasis currently (no minimum PASI or BSA) or skin psoriasis in the past documented by a dermatologist * Age 18-85 Exclusion Criteria: * History of IL-17 inhibitor use (other therapies including TNF inhibitors or non- biologics DMARDS in the past are acceptable) * Inflammatory bowel disease * Metal implants or other concerns for use of MRI * Active infection * Patients may have a history of self-reported psoriatic arthritis but may not have active PsA at the time of screening. * We will exclude patients with onychomyosis of the fingernails on clippings

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'Intervention-Secukinumab', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE', 'maskingDescription': 'Open Label'}}, 'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}}

2024-02-20